Cargando…

Is serum total bilirubin a predictor of prognosis in arteriosclerotic cardiovascular disease? A meta-analysis

The protective role of serum total bilirubin, a widely recognized antioxidant, has been approved by numerous updating studies. However, regarding the effect of high serum total bilirubin level (STBL) in arteriosclerotic cardiovascular disease (ASCVD) are conflicting in different sources of data. We,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lan, Yang, Liu, Huan, Liu, Jinbo, Zhao, Hongwei, Wang, Hongyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824698/
https://www.ncbi.nlm.nih.gov/pubmed/31626117
http://dx.doi.org/10.1097/MD.0000000000017544
_version_ 1783464780695076864
author Lan, Yang
Liu, Huan
Liu, Jinbo
Zhao, Hongwei
Wang, Hongyu
author_facet Lan, Yang
Liu, Huan
Liu, Jinbo
Zhao, Hongwei
Wang, Hongyu
author_sort Lan, Yang
collection PubMed
description The protective role of serum total bilirubin, a widely recognized antioxidant, has been approved by numerous updating studies. However, regarding the effect of high serum total bilirubin level (STBL) in arteriosclerotic cardiovascular disease (ASCVD) are conflicting in different sources of data. We, therefore, performed this meta-analysis to evaluate the influence of STBL on risk of ASCVD. Four databases were used to identify the literature with a date of search of January, 2019. Finally, a total of 20 studies had been adopted. ASCVD was defined as acute coronary syndrome, stable angina, coronary revascularization, atherosclerotic stroke or transient ischemic attack, and peripheral arterial disease (PAD). All relevant data were collected from studies meeting the inclusion criteria. A total of 20 published studies (323,891 cases) met the inclusion criteria. The meta-analysis revealed that, in studies excluding heterogeneity, STBL was significantly positively related to in-hospital cardiovascular mortality (odds ratio [OR] 2.82, 95% confidence interval [CI] 1.83–4.36, Z = 4.69, P < .001) and major adverse cardiac events (OR 1.88, 95% CI 1.414–2.491, Z = 4.36, P < .001), also negatively associated with prognosis of acute myocardial infarction, pooled hazard ratio (HR) = 0.804 (95% CI 0.700–0.923, Z = 3.08, P = .002). The correlation similarity was also reflected in terms of patients with stroke (HR 0.78, 95% CI 0.70–0.88, Z = 4.24, P = .003). Combined analysis revealed that lower STBL was significantly associated with PAD, pooled OR = 0.91 (95% CI 0.85–0.98, Z = 2.39, P = .017). In general analysis, a conclusion can be drawn, that higher STBL was significantly negative correlated with cardiovascular disease, pooled HR = 0.83 (95% CI 0.73–0.94, Z = 3.02, P = .003). Higher STBL significantly improved the prognosis of ASCVD; furthermore, STBL was an important factor in the long-term prognosis of vascular-related disease prevention and can be used as a predictor in vascular-related disease risk prediction.
format Online
Article
Text
id pubmed-6824698
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-68246982019-11-19 Is serum total bilirubin a predictor of prognosis in arteriosclerotic cardiovascular disease? A meta-analysis Lan, Yang Liu, Huan Liu, Jinbo Zhao, Hongwei Wang, Hongyu Medicine (Baltimore) 3400 The protective role of serum total bilirubin, a widely recognized antioxidant, has been approved by numerous updating studies. However, regarding the effect of high serum total bilirubin level (STBL) in arteriosclerotic cardiovascular disease (ASCVD) are conflicting in different sources of data. We, therefore, performed this meta-analysis to evaluate the influence of STBL on risk of ASCVD. Four databases were used to identify the literature with a date of search of January, 2019. Finally, a total of 20 studies had been adopted. ASCVD was defined as acute coronary syndrome, stable angina, coronary revascularization, atherosclerotic stroke or transient ischemic attack, and peripheral arterial disease (PAD). All relevant data were collected from studies meeting the inclusion criteria. A total of 20 published studies (323,891 cases) met the inclusion criteria. The meta-analysis revealed that, in studies excluding heterogeneity, STBL was significantly positively related to in-hospital cardiovascular mortality (odds ratio [OR] 2.82, 95% confidence interval [CI] 1.83–4.36, Z = 4.69, P < .001) and major adverse cardiac events (OR 1.88, 95% CI 1.414–2.491, Z = 4.36, P < .001), also negatively associated with prognosis of acute myocardial infarction, pooled hazard ratio (HR) = 0.804 (95% CI 0.700–0.923, Z = 3.08, P = .002). The correlation similarity was also reflected in terms of patients with stroke (HR 0.78, 95% CI 0.70–0.88, Z = 4.24, P = .003). Combined analysis revealed that lower STBL was significantly associated with PAD, pooled OR = 0.91 (95% CI 0.85–0.98, Z = 2.39, P = .017). In general analysis, a conclusion can be drawn, that higher STBL was significantly negative correlated with cardiovascular disease, pooled HR = 0.83 (95% CI 0.73–0.94, Z = 3.02, P = .003). Higher STBL significantly improved the prognosis of ASCVD; furthermore, STBL was an important factor in the long-term prognosis of vascular-related disease prevention and can be used as a predictor in vascular-related disease risk prediction. Wolters Kluwer Health 2019-10-18 /pmc/articles/PMC6824698/ /pubmed/31626117 http://dx.doi.org/10.1097/MD.0000000000017544 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 3400
Lan, Yang
Liu, Huan
Liu, Jinbo
Zhao, Hongwei
Wang, Hongyu
Is serum total bilirubin a predictor of prognosis in arteriosclerotic cardiovascular disease? A meta-analysis
title Is serum total bilirubin a predictor of prognosis in arteriosclerotic cardiovascular disease? A meta-analysis
title_full Is serum total bilirubin a predictor of prognosis in arteriosclerotic cardiovascular disease? A meta-analysis
title_fullStr Is serum total bilirubin a predictor of prognosis in arteriosclerotic cardiovascular disease? A meta-analysis
title_full_unstemmed Is serum total bilirubin a predictor of prognosis in arteriosclerotic cardiovascular disease? A meta-analysis
title_short Is serum total bilirubin a predictor of prognosis in arteriosclerotic cardiovascular disease? A meta-analysis
title_sort is serum total bilirubin a predictor of prognosis in arteriosclerotic cardiovascular disease? a meta-analysis
topic 3400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824698/
https://www.ncbi.nlm.nih.gov/pubmed/31626117
http://dx.doi.org/10.1097/MD.0000000000017544
work_keys_str_mv AT lanyang isserumtotalbilirubinapredictorofprognosisinarterioscleroticcardiovasculardiseaseametaanalysis
AT liuhuan isserumtotalbilirubinapredictorofprognosisinarterioscleroticcardiovasculardiseaseametaanalysis
AT liujinbo isserumtotalbilirubinapredictorofprognosisinarterioscleroticcardiovasculardiseaseametaanalysis
AT zhaohongwei isserumtotalbilirubinapredictorofprognosisinarterioscleroticcardiovasculardiseaseametaanalysis
AT wanghongyu isserumtotalbilirubinapredictorofprognosisinarterioscleroticcardiovasculardiseaseametaanalysis